Return to work after breast cancer diagnosis: an observational prospective study in Brazil (2018)
- Authors:
- Autor USP: HOFF, PAULO MARCELO GEHM - FM
- Unidade: FM
- DOI: 10.1002/cncr.31735
- Subjects: NEOPLASIAS MAMÁRIAS; QUALIDADE DE VIDA NO TRABALHO; SOBREVIDA
- Language: Inglês
- Imprenta:
- Source:
- Status:
- Artigo possui acesso gratuito no site do editor (Bronze Open Access)
- Versão do Documento:
- Versão publicada (Published version)
- Acessar versão aberta:
-
ABNT
LANDEIRO, Luciana Castro Garcia et al. Return to work after breast cancer diagnosis: an observational prospective study in Brazil. Cancer, v. 124, n. 24, p. 4700-4710, 2018Tradução . . Disponível em: https://doi.org/10.1002/cncr.31735. Acesso em: 07 abr. 2026. -
APA
Landeiro, L. C. G., Gagliato, D. M., Fede, A. B., Fraile, N. M., López, R. V. M., Fonseca, L. G. da, et al. (2018). Return to work after breast cancer diagnosis: an observational prospective study in Brazil. Cancer, 124( 24), 4700-4710. doi:10.1002/cncr.31735 -
NLM
Landeiro LCG, Gagliato DM, Fede AB, Fraile NM, López RVM, Fonseca LG da, Petry V, Testa L, Hoff PMG, Mano MS. Return to work after breast cancer diagnosis: an observational prospective study in Brazil [Internet]. Cancer. 2018 ; 124( 24): 4700-4710.[citado 2026 abr. 07 ] Available from: https://doi.org/10.1002/cncr.31735 -
Vancouver
Landeiro LCG, Gagliato DM, Fede AB, Fraile NM, López RVM, Fonseca LG da, Petry V, Testa L, Hoff PMG, Mano MS. Return to work after breast cancer diagnosis: an observational prospective study in Brazil [Internet]. Cancer. 2018 ; 124( 24): 4700-4710.[citado 2026 abr. 07 ] Available from: https://doi.org/10.1002/cncr.31735 - Should patients with advanced colorectal cancer and ECOG 3/4 be treated with chemotherapy?
- Primary prevention of colorectal cancer: Myth or reality?
- Drogas moleculares
- Perspectivas no cuidado dos tumores gastrointestinais
- Obesidade e câncer
- Combination of capecitabine and oxaliplatin is an effective treatment option for advanced neuroendocrine tumors
- Expression of ERCC1, Bcl-2, Lin28a, and Ki-67 as biomarkers of response to first-line platinum-based chemotherapy in patients with high-grade extrapulmonary neuroendocrine carcinomas or small cell lung cancer
- Evidence-based recommendations for gastrointestinal cancers during the COVID-19 pandemic by the Brazilian Gastrointestinal Tumours Group
- Lack of association between ERCC1 expression in biliary tract malignancy and response to chemotherapy
- Combination of irinotecan and a platinum agent for poorly differentiated neuroendocrine carcinomas
Informações sobre a disponibilidade de versões do artigo em acesso aberto coletadas automaticamente via oaDOI API (Unpaywall).
Por se tratar de integração com serviço externo, podem existir diferentes versões do trabalho (como preprints ou postprints), que podem diferir da versão publicada.
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
